Collectively, these discoveries synergize with established targets such as ACSL4 and FABP5, to map a dynamic interplay of redox imbalance, metabolic dysregulation, and cell-type-specific vulnerability, thereby advancing therapeutic strategies for ferroptosis modulation in stroke. Here, FABP5 is linked to stroke disorder.